Why the study?
How can the risk of major bleeding events be minimized in patients with nonvalvular atrial fibrillation receiving direct oral anticoagulants for stroke prevention?
How can the risk of major bleeding events be minimized in patients with nonvalvular atrial fibrillation receiving direct oral anticoagulants for stroke prevention?
A structured approach to DOAC prescribing, including appropriate dosing and risk factor modification, can minimize bleeding risks and increase physician confidence in stroke prevention for AF.
Answers are grounded in this paper and cite their sources.
Strategies to minimize bleeding may support DOAC use in high-risk AF; leaves open need for prospective validation.
Many primary care physicians are wary about using direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AF). Factors such as comorbidities, concomitant medications, and alcohol misuse increase concerns over bleeding risk, especially in elderly and frail patients with AF. This article discusses strategies to minimize the risk of major bleeding events in patients with AF who may benefit from oral anticoagulant therapy for stroke prevention. The potential benefits of the DOACs compared with vitamin K antagonists, in terms of a lower risk of intracranial hemorrhage, are discussed, together with the identification of reversible risk factors for bleeding and correct dose selection of the DOACs based on a patient's characteristics and concomitant medications. Current bleeding management strategies, including the new reversal agents for the DOACs and the prevention of bleeding during preoperative anticoagulation treatment, in addition to health care resource use associated with anticoagulation treatment and bleeding, are also discussed. Implementing a structured approach at an individual patient level will minimize the overall risk of bleeding and should increase physician confidence in using the DOACs for stroke prevention in their patients with nonvalvular AF.
No takes yet. Share an insight, caveat, or question.
Jeffery S Habert (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: